Objective: To add quantitative muscle MRI to the clinical trial toolbox for facioscapulohumeral muscular dystrophy (FSHD) by correlating it to clinical outcome measures in a large cohort of genetically and clinically well-characterized patients with FSHD comprising the entire clinical spectrum.
Facioscapulohumeral muscular dystrophy (FSHD) is one of the commonest forms of adult muscular dystrophy. 1 It is characterized by slowly progressive weakness of the facial and shoulder girdle muscles, followed by leg and trunk muscles. 2 Disease course and severity are highly variable, even within families, ranging from asymptomatic gene carriers to wheelchair-bound patients. Since the discovery of the (epi)genetic origin of the disease, new therapeutic strategies are being developed and clinical trials are at the horizon. Consequently, there is an urgent need for a clinical trial toolbox, including patient registries, biomarkers, and clinical outcome measures. 3 While clinical outcome measures provide direct measures of patient functioning or ability, they may not be sensitive enough to capture changes in this slowly progressive disorder. Especially for early phase clinical trials, biomarkers that detect subtle changes in muscle pathology are required. Quantitative muscle MRI may provide such a biomarker 4 ; however, evidence of its correlation to clinical outcome measures still has to be established. Previous studies on this correlation have mostly used qualitative or ordinal, and thus nonlinear, MRI data. [5] [6] [7] [8] [9] [10] [11] Studies that have used quantitative MRI comprised small cohorts with a maximum of 50 patients and none of them included patients across the entire FSHD clinical spectrum. [12] [13] [14] [15] [16] We enrolled a large cohort of patients with genetically confirmed and clinically heterogeneous FSHD. This study presents baseline data on quantitative MRI of the leg muscles and its correlation to multiple clinical outcome measures to determine the value of muscle MRI as a component of the FSHD trial toolbox.
METHODS Patients. We included patients with genetically confirmed FSHD 18 years and older at the neurology department of the Radboud University Medical Center, Nijmegen, the Netherlands, between 2014 and 2015. Asymptomatic gene carriers (individuals who reported no symptoms, with or without signs of FSHD on clinical examination) with at least one affected family member were also included. We included patients with FSHD1 and patients with FSHD2 to compare the groups. Exclusion criteria were contraindications for MRI (e.g., claustrophobia or metallic implants).
Standard protocol approvals, registrations, and patient consents. The study protocol was approved by the regional medical ethics committee. All patients signed informed consent.
Clinical outcome measures. In all patients, multiple clinical outcome measures were scored. The motor function measure (MFM) is a 32-item scale assessing the severity of the motor deficit in neuromuscular diseases; outcomes range from 0% to 100%, in which 100% implies no motor deficits. 17 The 6-minute walking test (6-MWT) is used to evaluate functional capacity in neuromuscular disorders and indicates the maximum distance that a patient is able to walk in 6 minutes. 18, 19 The clinical severity score by Ricci et al. 20 (Ricci score) indicates clinical severity on a 10-point scale in which 0 indicates no muscle weakness and 10 indicates wheelchair dependency. The Ricci score assumes a fixed sequence of muscle involvement and is less suitable for patients with an atypical disease course. We therefore included the FSHD clinical score, which evaluates strength and functionality of 6 muscle regions separately. 21 This score ranges from 0 to 15, where 0 indicates no muscle weakness and 15 severe muscle weakness in all muscle groups. Manual muscle testing was scored using a 6-point Medical Research Council (MRC) gradation ranging from 0 (no muscle contraction) to 5 (maximal muscle strength) for hip flexion, hip abduction, knee flexion, knee extension, foot dorsal flexion, and foot plantar flexion. 22 The maximum isometric contraction of the knee extensors was assessed using fixed dynamometry, scored in Newtons. All clinical scores were obtained by one trained physician (K.M.).
MRI acquisition. All MRI examinations were performed on the same 3T MRI system (TIM Trio; Siemens, Erlangen, Germany) using a scanning protocol adapted from previous studies. 14, 15 Participants were placed feet first supine in the scanner. Scout images were made in 3 orthogonal directions to position imaging slices for subsequent scans. MRI analysis. The water and fat image of the Dixon sequence were used to create a fat fraction map using MATLAB according to the following equation:
Fat Fat1Water . The fat fraction map was used to draw region of interest (ROI) per muscle using ImageJ software (figure 1). 23 All drawn ROIs were checked by a second clinician, and interrater variability was assessed on a subset of 10 scans (380 muscles). Muscle cross-sectional area and fat fractions were calculated per ROI. We evaluated 12 upper leg muscles and 7 lower leg muscles. ROIs were drawn at 2 different slices using the localizer sequences: in the upper leg at one-third and twothirds of the distance between the spina iliaca anterior superior and the upper edge of the patella. In the lower leg, we used slices at two-thirds and 5/6 of the distance between the lateral malleolus and the lower edge of the patella for the gastrocnemius and onethird and two-thirds of the distance between these landmarks for the other lower leg muscles. TIRM images were visually assessed for the presence of signal hyperintensity in each muscle by a radiologist and the first author (K.M.). When there was discrepancy between the 2 scores, another author (C.G.C.H.) also assessed the image.
Statistical analyses. All statistical analyses were performed using IBM SPSS Statistics (SPSS Inc., Chicago, IL), version 22. Spearman rho analyses were used to calculate bivariate correlations, independent t test to compare means. A x 2 test was used to search for an association between TIRM positivity and sex. Simple linear regression analyses were used for the relation between duration of symptoms and mean fat fraction and clinical outcome measures. Interrater variability was assessed using intraclass correlation coefficient (CC). p Values #0.05 were considered statistically significant. Notably, the rectus femoris was often fatty infiltrated, while the rest of the quadriceps muscles were normal. Knee extension strength was tested in the seated position. In this position, knee extension is primarily driven by the vastus muscles, because the Nine asymptomatic gene carriers were included. Four had no signs of FSHD on examination, 2 had mild scapular winging, 2 had a combination of mild scapular winging and minimal facial weakness, and 1 had unilateral mild hamstring weakness. Two asymptomatic gene carriers with signs of FSHD showed fatty infiltration of leg muscles: one had a rectus femoris muscle with a fat fraction of 23.5%; another had elevated fat fractions in the rectus femoris, adductor longus, and soleus muscles of 36.2%, 67.0%, and 23.3%, respectively.
In patients without any functional involvement of the leg muscles (Ricci scores ,2.5, n 5 43), specific muscles showed elevated mean fat fractions: semimembranosus (19.7% 6 19.5%), rectus femoris (16.3%, 619.0), adductor longus (13.9%, 614.7), tibialis anterior (11.7%, 68.4), adductor magnus (11.1%, 68.6). Three patients had mild weakness of the dorsiflexors of the ankle on manual muscle testing and one 32-year-old woman showed knee extensor weakness on quantitative muscle assessment (227 N). Excluding these patients from the analyses did not change the results. Regression analysis was performed to assess associations between disease duration and clinical measures. In this cohort, 10 years longer disease duration was associated with 7.5% (95% confidence interval [CI] 5.9-9.1) higher mean fat fraction for the total legs, 7.7% (95% CI 5.8-9.5) lower score on the MFM, 44.8 (95% CI 32.2-57.5) meters less on the 6-MWT, and 1.7 (95% CI 1.3-2.1) and 0.8 (95% CI 0.6-1.1) points higher on the FSHD clinical score and Ricci score, respectively.
Pattern of muscle involvement. Fat fraction per muscle ranged from 2% to 98%. Of all 5,243 leg muscles, 46.4% showed hardly any fatty infiltration (fat fractions ,10%). About a quarter (23.5%) was severely fatty infiltrated (fat fractions .60%). Strong interrater agreement was found for the assessment of fatty infiltration (intraclass correlation coefficient 0.992; in later disease stages are also the ones that are affected early (figure 3). Asymmetric involvement in at least one muscle pair, defined as a difference of .10% in fat fractions between sides, was found in 80.7% (113/140) of all patients. However, most muscles were symmetrically affected; i.e., 20.1% of all muscle pairs showed asymmetry in fat fraction between sides. Of those muscle pairs with asymmetry, there was rightsided preference in 53.0%.
Facioscapulohumeral muscular dystrophy type 2. In 8 patients with FSHD2, we found a similar pattern of muscle involvement and asymmetry compared to FSHD1. Most severely affected were semimembranosus, rectus femoris, adductor longus, adductor magnus, gastrocnemius medialis, and tibialis anterior. Two individuals with combined FSHD1 and FSHD2 had a very severe phenotype with mean fat fraction of 65.5% and 73.0%, which was much higher than the mean total fat fraction of 23.8% of the patients with FSHD1 and 31.6% of the patients with FSHD2.
TIRM hyperintensity. In 68 out of 140 patients (48.6%), we found at least one muscle with a hyperintense signal on TIRM sequence (TIRM-positive). A total of 5,240 muscles were assessed for TIRM hyperintensity and 186 were positive (3.5%) ( figure 3 ). The muscles that were positive most frequently were the tibialis anterior (12.9%), gastrocnemius medialis (11.8%), and vastus lateralis (8.9%). The tibialis posterior, peroneus, and adductor longus rarely displayed TIRM hyperintensity (0%-0.4%). The presence of TIRM hyperintensity per muscle is reported in table e-1. Out of 186 TIRM-positive muscles, 29 (15.6%) had a normal fat fraction (,10%) and 23 (12.4%) a high fat fraction (.60%). In 73.1% of TIRMpositive muscles, the TIRM hyperintense area was found directly adjacent to a fatty infiltrated area. TIRM-positive muscles were most frequently found in patients with moderately severe disease (Ricci score 4-8). None was found in patients with severity scores of 0 or 1. A total of 62.9% of TIRM-positive muscles were found in the right leg, although the difference with the number in the left leg was nonsignificant (p 5 0.157), except for the vastus lateralis (p 5 0.001), tibialis anterior (p 5 0.000), and extensor digitorum longus (p 5 0.012). Significantly more male patients had TIRM-positive muscles than did female patients: 45 men vs 23 women (x 2 5 5.1; p 5 0.024). In addition, the mean number of TIRM-positive muscles was significantly higher in men than in women (1.6 vs 0.9; p 5 0.04). They did not significantly differ in age, disease duration, FSHD type, repeat fragment size, or scores on clinical outcome measures.
Proximal-distal gradient. Overall, there was a mean decrease of fat fraction within muscles from distal to proximal of 3.9%, 63.7. A decrease from distal to proximal of .10% was found in 33.2% of the muscles (711/2,140). The adductor magnus, semimembranosus, tibialis anterior, and rectus femoris showed the largest distal to proximal gradient (mean decreases 9.3% 6 14.7%, 7.2% 6 18.4%, 6.9% 6 12.4%, and 4.9% 6 14.8%, respectively). A total of 162 of 2,140 (7.6%) individual muscles showed an increase of .10% from distal to proximal. In some muscles, we observed a gradient in fatty infiltration from distal to proximal, with a TIRM-positive front in unaffected muscle tissue proximally adjacent to fatty infiltrated muscle tissue (figure 4).
DISCUSSION This study provides a thorough description of the relation of quantitative muscle MRI with clinical measures in a large cohort of patients with FSHD comprising the entire clinical spectrum. It demonstrates that the mean total leg fat fraction on MRI correlates strongly with measurements of strength, clinical severity scores, and measures of overall functional activity, and thus validates MRI as a biomarker of disease severity. MRI was able to detect muscle changes in patients without any loss of leg muscle function, especially in the hamstring muscles, adductor muscles, and rectus femoris. Possibly, we did not find a loss of leg muscle function in these patients because of compensation by other muscles (of the same group), compensation within the muscle on a molecular level, or because limited fatty infiltration does not restrict the functional capacity of the muscle. Our finding of early MRI changes in individuals without leg muscle weakness suggests that MRI might be used to identify individuals and muscles at risk for clinical progression. The hamstrings, adductor muscles, and gastrocnemius medialis were the most frequently affected muscles. Most often spared were the tibialis posterior, gastrocnemius lateralis, and peroneus. The most frequently and most severely affected muscles were also the muscles that were affected in patients in early disease stages. Our findings support the hypothesis that muscles become affected in a sequential order, and that muscles that become affected in later stages progress at a similar pace as early affected muscles. The pattern of involvement in fatty infiltration is in concordance with findings in a large qualitatively assessed FSHD cohort, although this cohort included only asymptomatic gene carriers or patients with a Ricci score of 5 and higher, indicating that no mildly affected patients were included. 5 We found a similar frequency of asymmetric muscle involvement as previous studies, 5,16 but we did not find a clear right side predominance for fatty infiltration in the lower extremities.
Recently, hyperintensities on TIRM sequence in FSHD muscles have been proposed to represent muscle edema, which is sometimes interpreted as active muscle inflammation, 15, 24, 25 and a marker for disease activity. The prevalence of TIRM-hyperintense muscles in this study (3.5%) is comparable to prevalences in the literature (3%-7%). In addition, we found a similar proportion of TIRM-positive muscles without fatty infiltration. TIRM-positive areas were often found near fatty infiltrated regions. In some muscles, there was a TIRM-positive front located proximally to the fatty infiltration, supporting the hypothesis that in many muscles fatty infiltration starts distally in the muscle. However, the muscles that were most frequently TIRM-positive were not the same muscles as those that were most severely or frequently fatty infiltrated. In addition, in mildly affected patients, fatty infiltrated muscles were more frequently observed than TIRM-positive muscles. These findings could indicate variation in the pathogenic mechanism, including different durations of the TIRM-positive phase, TIRM-positive areas that reverse to normal muscle tissue, and the occurrence of fatty infiltration without preceding TIRM positivity. The proportion of TIRM-positive muscles was higher in men than in women. 5 This suggests that there are sex-specific disease differences, possibly related to differences in reproductive hormones.
In all patients, we found a combination of normal and fatty infiltrated muscles, and in some also TIRMpositive muscles, supporting the hypothesis that FSHD is a muscle per muscle disease with separate muscles affected in different stages of disease. Longitudinal studies are required to further explore this hypothesis and its underlying mechanisms. Muscles of the trunk and upper limb could also be included in future studies.
The unique value of this study lies in the use of quantitative analysis of muscle fat fractions in a large genetically confirmed and clinically diverse cohort. For use as a biomarker, quantitative measurement is essential, since linear values can be used for parametric statistical analyses in contrast to ordinal scores. 26 This might be more sensitive to change over time compared to functional measures in this slowly progressive disorder. A previous study showed that quantitative assessment has a larger sensitivity and better accuracy compared to a semiquantitative visual score. 16 In addition, it can provide information on the pattern of involvement not only between but also within different muscles. The single-center, singleevaluator design of this study avoids interrater variability and increases the reliability of correlations between fat fractions and clinical measures. However, a limitation of this design is the decrease in the external validity. Results regarding disease duration should be interpreted with caution since age at disease onset was collected retrospectively.
For clinical trials, we propose quantitative muscle MRI assessment in addition to clinical outcome measures that directly measure patient functioning, like the motor function measure. The motor function measures, however, showed a ceiling effect in mildly affected patients. Although a good reliability and validity of the scale is suggested for patients with FSHD, its psychometric properties, including its target population, should be evaluated in more detail. 27 Qualitative MRI evaluations will remain useful, for example in assessing the presence of TIRM hyperintensities and detecting subtle muscular changes that do not show in the clinical examination of the patient.
This study shows a strong correlation of quantitative muscle MRI with different clinical outcome measures, especially with the motor function measure. Since quantitative muscle MRI also has good clinimetric properties, it is a promising biomarker representative of disease severity. For clinical trials, we propose to include quantitative muscle MRI and the motor function measure in the FSHD trial toolbox.
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